Contact Us
Drug Search Results
More Filters [+]

Sapitinib

Alternative Names: sapitinib, azd8931
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Inhibitor,ERBB2 Inhibitor,ERBB3 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sapitinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Menopause

Phase 2: Breast Cancer|Esophageal Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Colorectal Cancer

Phase 1: Breast Cancer|Healthy Volunteers|Ranula|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2006-7041-83/hah

P4

Not yet recruiting

Menopause

2021-08-02

PANTHER

P2

Completed

Colorectal Cancer

2019-08-02

THYME

P2

Completed

Breast Cancer

2015-02-05

CHIVE

P1

Terminated

Breast Cancer

2013-03-01

Recent News Events

Date

Type

Title

04/01/2024

PubMed

 Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.

02/22/2024

PubMed

 Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.

02/18/2024

PubMed

 Bulk and single-cell sequencing identified a prognostic model based on the macrophage and lipid metabolism related signatures for osteosarcoma patients.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions